NCT00493077View on ClinicalTrials.gov

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Multiple Sclerosis
Interventions
DRUG

low immunogenic interferon-beta-1a

dosage and frequency as per Biogen Idec protocol

Trial Locations (5)

416 85

Research Site, Gothenburg

Unknown

Coordinating Research Site, Huddinge

551 85

Research Site, Jönköping

651 85

Research Site, Karlstad

141 86

Research Site, Stockholm

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY